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The placenta plays a central role in governing local circulatory system that mediates maternal condition and fetal growth. In
early gestational phases, the placenta exerts properties of invasion and neovascularization for successful placentation. Extravillous
invasive trophoblasts replace uterine endometrial vasculature and establish local blood pathway to obtain oxygen and nutrients
from the mother. In later phases, the placenta promotes villous angiogenesis and vascular maturation that are ﬁnely controlled by
angiogenicandantiangiogenicmolecules. Among variousmolecules involved in placental neovascularization,vascularendothelial
growth factor receptors (VEGFRs) and angiotensin II receptor type 1 (AT1) mediate important signaling pathways for maternal
circulatory system and fetal growth. VEGFR1 and VEGFR2 are functional receptors for placental growth factor (PlGF) and VEGF,
respectively, and PlGF-VEGFR1 and VEGF-VEGFR2 interactions are disturbed in many preeclamptic patients by excess amount
ofsoluble form of VEGFR1 (alsonamed sFlt1), a naturalPlGF/VEGF antagonist.Recent studies have disclosed that excessive sFlt1
production in the placenta and aberrantAT1 signalingin the motherare closelyassociatedwith thepathology ofpreeclampsia and
intrauterine growth restriction (IUGR). In this paper, neovascularization of the placenta and pathological events associated with
disrupted balance between angiogenic and antiangiogenic signalingin preeclampsia are discussed.
1.Introduction
The placenta is a special organ that organizes fetal growth
and maternal condition during gestation, and it terminates
self-role as the fetomaternal mediator immediately after
delivery. Pathological conditions during pregnancy such as
preeclampsia and intrauterine growth restriction (IUGR)
are closely associated with placental dysfunction. Maternal
preeclamptic conditions frequently result in IUGR and
premature delivery, and many studies on preeclampsia have
improvedourunderstandingofabnormalplacentationinthe
context of shallow invasion and production of unfavorable
proinﬂammatory factors. In the circulation of preeclamptic
patients, some antiangiogenic molecules are detectable at
excess levels [1–3], for example, soluble form of vascular
endothelial growth factor (VEGF) receptor 1 (sVEGFR1,
also named sFlt1) and soluble form of endoglin (sEng,
also named sCD105). sFlt1 suppresses VEGF-mediated and
placental growth factor- (PlGF-) mediated signaling, and
sEng disturbs transforming growth factor β-( T G F β-) medi-
ated signaling [2, 3]. These antiangiogenic cytokines are
believed to be released from the placenta in response to
hypoxic microenvironment. Once maternal vascular resis-
tance increases, blood pressure per se potentially induces
f u r t h e rd y s f u n c t i o n ss u c ha sg l o m e r u l a re n d o t h e l i o s i sa n d
disruption of blood brain barrier. Therefore, spatiotemporal
events that occur to the placenta and placenta-derived
factors that induce maternal systemic dysfunction are very
important for better understanding of pathological courses
of preeclampsia and for better management of preeclamptic
pregnancies. In this paper, we summarize current under-
standing of placental development and pathophysiology of
preeclamptic placentas, with special attention on antiangio-
genic signaling pathways.2 Journal of Pregnancy
2.StructureofPlacentalVascularNetwork
Human term placenta is divided largely into three layers in
histology (Figure 1): (1) basal plate (maternal surface) and
anchoring villi (most distal extensions of the primary stem
villi) that interact directly with maternal endometrium, (2)
terminal villous unit where gas and nutrient exchanges take
place actively; (3) chorionic plate (fetal-side surface) and
stem villi that consist of dense connective tissue containing
larger fetal vessels. Amnion and chorion cover chorionic
plate, and the umbilical cord collects chorionic arteries and
veins on chorionic plate [4].
Fundamental structure of the placenta is established
during the ﬁrst half of gestation [5]. Terminal villous units
(tertiary villi that stems from secondary villi) include fetal
side capillaries lined by endothelial cells and outlining
trophoblasts(Figure 1). Inearlier stages, trophoblasts layeris
composed of cytotrophoblasts (inner layer) and syncytiotro-
phoblasts(outerlayer).Asthepregnancyprogresses, cytotro-
phoblasts layer become undetectable, and fetal capillaries are
placed in close proximity to intervillous maternal circulation
for maximizing gas exchange. Maternal blood space is lined
directly by terminally diﬀerentiated syncytiotrophoblasts
and not by endothelial cells, which is called hemochorial
interface [6].
Fetal weights increase almost twice during the last stage.
On the other hand, the weight of the placenta does not
increase signiﬁcantly in later stages [4]. Terminal villous
vasculature becomes ﬁnely diﬀerentiated and vascular beds
increase functional capacity of molecular exchanges between
mother and fetus [4, 5]( F i g u r e1). In preeclamptic placenta,
however, terminal villous units are poorly diﬀerentiated,
and distal villi are truncated (Figure 1). These pathological
changes are often accompanied by IUGR.
3.Pseudovasculogenesisand
Local Microenvironment
Establishment of blood pathway is critical for successful pla-
centation.Atinitial stages,extravillous trophoblastsinﬁltrate
uterine implantation site and undergo invasive phenotype,
remodeling endometrial tissue. Some of these trophoblasts
exert vasculogenic property and replace endothelial cells
of uterine spiral arteries (Figure 1). This process is called
“pseudovasculogenesis” or “epithelial-endothelial transfor-
mation” [7]. Invasive endovascular trophoblasts temporarily
form cellular plugs to restrict blood overﬂow during early
period (6–12 weeks of gestation). The mechanism is not
fully understood and some investigations argue against the
importance of plugs. Certain local factors such as tumor
necrosisfactorα(TNFα)an dT GFβmay aﬀectinvasive prop-
erties of extravillous trophoblasts and alter susceptibilities of
vascular constituent cells to trophoblasts-mediated stimuli
[8]. Remodeled spiral arteries show characteristic feature of
widened luminal diameter and degenerated vascular smooth
muscle cells. As we discuss later, failure of vascular remodel-
ingmaylead tomaternal preeclampticconditionsandIUGR.
Transformed trophoblasts that replace uterine spiral
arteries may express the endothelial markers such as CD31,
VE-cadherin, vascular cell adhesion molecule (VCAM)-1
and αvβ3i n t e g r i n[ 9, 10]. In addition, they potentially
express endothelial nitric oxide synthase (eNOS), sug-
gesting that they mimic endothelial cells morphologically
and functionally [11]. Such phenotypic transformation
is observed not only in placentation but also in tumor
neovascularization. Some types of tumor cells may acquire
endothelial cells-like features and form aberrant vascular
network where endothelial lining is missing, known as
“tumor vasculogenic mimicry” [12, 13]. These special
tumor cells may also express some endothelial markers
and vasculogenesis-related molecules such as VE-cadherin,
CD34 and CD105 [13, 14]. Tumor invasion is disorganized
whereas trophoblasts invasion is ﬁnely controlled by the
crosstalk between endometrial components and extravillous
trophoblasts. If the endometrium is ulcerated due to abor-
tion or other inﬂammatory events, local immune system
does not work properly and trophoblasts may aberrantly
invade deep layerof uterine smooth muscle. Such conditions
are called accrete, increate and percreta.
Tissue-speciﬁc proinﬂammatory microenvironment is
essential for proper placentation. Uterine natural killer
(uNK) cells are major local resident immune mediators
characterized by CD45+ CD69+ CD56bright and CD16−
[15–17]. uNK cells are thought to play important roles in
decidual reaction, remodeling of spiral arteries, and regu-
lating invasive properties of trophoblasts [16, 18]. Invasive
trophoblasts express unique repertoire of human leukocyte
antigens (HLA)-C, HLA-E and HLA-G [16, 17, 19, 20].
Classical MHC class I molecules HLA-A and HLA-B that
have polymorphism for initiating allograft rejection are not
expressed in extravillous trophoblasts. [16]. uNK cells have
both inhibitory and stimulatory surface receptors for regu-
lating trophoblasts invasion [15, 19]. For example, HLA-E in
trophoblasts interacts with NKG2 (CD94) in uNK cells [19],
and attenuates cytotoxicity of uNK cells against invading
trophoblasts. HLA-Cin trophoblastsinteractswith killer-cell
immunoglobulin-like receptor( K I R ) - f a m i l yi nu N Kc e l l s ,
and speciﬁc combination of maternal KIR and fetal HLA-
C contributes to successful placentation [21], though the
actual mechanism remains to be further investigated [22].
Hyperactivated uNK cells may produce high amounts of
unfavorable cytotoxic factors such as granulysin and inhibit
trophoblastsinvasionbyinducingapoptosis[23].Inaddition
to uNK cells, CD14+ CD68+ macrophages also participate
in proinﬂammatory crosstalk between spiral arteries and
extravillous trophoblasts. In basal plate, local macrophages
produce TNFα that potentially induces trophoblasts apop-
tosis [24]. If these cytotoxic cytokines are overproduced
by maternal-side immune cells, the case may result in
miscarriage or shallow invasion.
4.Predisposing FactorsofPreeclampsia
The onset of preeclampsia may depend not only on a sole or
a few pathological events. It seems rather to be triggered byJournal of Pregnancy 3
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Figure 1: Schema and histology of the placenta. Endothelial cells of spiral arteries are replaced by cytokeratin- (CK-) positive extravillous
trophoblasts (upper left). In terminal villous units, two distinct blood pathways exist, that is, maternal blood ﬂow (M) and fetal circulation
(F) that are separated by syncytiotrophoblasts. Villi are ﬁnely diﬀerentiated in normal term placentas, but poorly branched with ﬁbrinous
exudate and aggregation of syncytiotrophoblastic nuclei in preeclamptic placenta.
a load of various predisposing factors that induce circulatory
disorders [25]. After the onset of hypertension, shear stress
on vascular wall may lead to further deterioration of feto-
maternal conditions. With regard tomaternal geneticpredis-
position, special patterns of angiotensinogen gene variants
and quantitative trait loci (QTL) on some chromosomes
including AGT, STOX1, 5q, 10q and 13q QTL have been
reported [26–29]. Maternal KIR-AA and fetal HLA-C2, but
not fetal HLA-C1, lead to increased risk of preeclampsia
[21]. Although the backgrounds and progression patterns of
preeclampsiamayvaryamongcases,itiswidelyacceptedthat
poor placentation at early gestational stages is an important
predisposing condition for disease development. Narrowed
blood canals due to insuﬃcient arterial remodeling make
the placenta hypoxic, and in response, a series of proinﬂam-
matory factors are released from the placenta that damage
maternalcirculatorysystem. Thisprocessiscomposedoftwo
stages, that is, poor placentation of early gestational period
(stage I) and maternal systemic dysfunction in later period
(stage II) [25].
5.KeyMoleculesInvolved inthe
Pathophysiologyof Preeclampsia
There are a wide variety of factors that potentially damage
maternal blood vessels. Neurokinin-B, a family of peptides
tachykinins, had been proposed to be a responsible molecule
that would cause preeclampsia [30]. Although later studies
did not fully approve the notion [31], a study demonstrated
that neurokinin-B, with the help of thromboxane A2-
(TXA2-) like molecule, suppressed angiogenic activities
in vitro by downregulating VEGF, VEGFR1 and VEGFR2
in cultured endothelial cells [32]. Cumulative studies on
preeclampsia have elucidated signaling crosstalks among
PlGF/VEGF, RAS, and classic eicosanoids such as prosta-
cyclin and TXA2. In this paper, we focus on some soluble
factors that are thought to exert antiangiogenic properties in
the circulation of preeclamptic patients.
5.1. Soluble Form of VEGFR1 (sVEGFR1, sFlt1). sFlt1 is
a natural soluble factor, and it is the truncated version
of VEGFR1 that lacks transmembrane and intracellular
signaling domains [33]. sFlt1 generally inhibits the signaling
pathways of angiogenesis by binding to free forms of
VEGF and PlGF [33, 34]. With regard to physiological and
pathological conditions in vivo,sFlt1 is known to be essential
for physiological avascularity in the cornea [35]. sFlt1 is also
produced in some types of tumor tissues such as colorectal
and breast cancers [36, 37]. In clinical studies on these
tumors, the expression level of sFlt1 was correlated with
favorable prognosis, probably owing to its antiangiogenic
property.
In the middle stage of gestation, free VEGF and PlGF
levels in maternal circulation increase in normal pregnancy,
butnot in preeclampticcases. On the otherhand, circulatory
sFlt1 levels in preeclamptic women are abnormally higher
than those in normal controls [38–40]. Predominance of
sFlt1 leads to systemic vascular dysfunction by interfering4 Journal of Pregnancy
with homeostatic activities of VEGF and PlGF [33, 41–43].
Excess amount of sFlt1 is produced mainly by villous
trophoblasts stimulated by the sera of preeclamptic patients,
suggesting that certain maternal-side factor(s) such as ago-
nistic autoimmune antibody against angiotensin II receptor
type 1 (AT1) induce antiangiogenic signaling in syncytiotro-
phoblasts. Recently, involvement of another splice variant of
sFlt1 has been reported [44, 45]. Sela et al. named it sFlt1-
14 [45] and suggested that this alternative variant might be
a predominant inhibitor of VEGF. Although contribution of
sFlt1-14 for regulating PlGF-mediated signaling is a subject
for future study, their studies indicate that more than one
soluble factor aﬀects VEGFRs properties in preeclamptic
placentas.
5.2. PlGF and VEGFR1. Heterozygous VEGF+/− embryos
die due to vascular defects [46], whereas PlGF deﬁcient
mice are fertile with normal looking. Therefore, the roles of
PlGF are not fully understood and this molecule is thought
to be dispensable for embryonic vascular development in
contrast to VEGF [47]. PlGF binds to VEGFR1 but not to
VEGFR2 [48, 49], and VEGFR1−/− mice died in utero with
an overgrowth of endothelial cell-like abnormal cells [50].
Since the kinase activity of VEGFR2 is about ten-fold higher
than that of VEGFR1 [51], actual roles of PlGF-VEGFR1
axis seem to be complex. Collecting the studies on various
vascular diseases including tumor angiogenesis, it is likely
that PlGF has both angiogenic and antiangiogenic properties
depending on pathophysiological conditions. PlGF may
displace VEGF from VEGFR1 and direct VEGF towards
VEGFR2, accelerating angiogenesis [48]. On the other hand,
PlGF/VEGF heterodimers potentially suppress angiogenesis
induced by VEGF homodimers [52–54].
In pregnancy, plasma concentration of PlGF is elevated
exponentially during middle stages (100–1000pg/mL). The
sFlt1 level is also matched to that of PlGF [40], whereas the
VEGF level is around 5–10pg/mL [55]. The considerable
diﬀerenceofmeanexpression levelsbetweenPlGFandVEGF
indicates that PlGF may play a predominant role in feto-
placental development, and that circulating PlGF level may
reﬂect pathological conditions of pregnancy as a sensitive
marker [40,55].Tayade etal.suggested thatlocalPlGFmight
accelerate functional maturation of uNK cells for the process
of trophoblast invasion. In PlGF deﬁcient mice, binucleate
uNK cells abnormally increased in number, and smooth
muscle layer of spiral arteries were thickened, indicating
that the process of vascular remodeling was disturbed in
some degree [56]. Although preeclamptic symptom was
not reported in PlGF deﬁcient mice, in human prospective
study, PlGF is shown to be suppressed at ﬁrst trimester
before clinical symptoms become overt [57, 58]. The results
suggest that PlGF upsurge is probably hampered by some
predisposing factors atinitialstage,andthatlow-PlGF milieu
contributes to the development of preeclampsia as an early
event rather than as a consequence of later stages.
5.3. Soluble Form of Endoglin (sCD105, sEng) and Other
Soluble Factors. The concentrations of sEng (sCD105) are
signiﬁcantly elevated in preeclamptic patients, especially in
severe cases named HELLP syndrome (Hemolysis, Elevated
Liver enzyme, Low Platelets syndrome) [3]. CD105 is an
auxiliary receptor for TGFβ1a n dT G F β3, and is expressed
in various cell types including endothelial cells, vascular
smooth muscle cells, and so on [3, 59, 60]. CD105 deﬁcient
mice embryos die at mid gestation due to poor vascular
smooth muscle development [61]. In in vitro study using
cultured endothelial cells, sEng (sCD105) was shown to
inhibit capillary tube formation and attenuate vasodilation
induced by TGFβ1a n dT G F β3[ 3]. In the rat treated with
sEng adenovirus, TGFβ-mediated signaling was suppressed,
leading to eNOS reduction and impaired vasodilation of
renal microvessels. These results support the notion that
CD105 is indispensable for embryonic neovascularization
and that sEng inhibits TGFβ-mediated vascular activities.
On the other hand, in human trophoblasts, TGFβ-CD105
axis seems to negatively regulate cellular activities [62]. The
expression levels of HIF-1α and TGFβ3 were upregulated
underhypoxia intheearly gestationalstage,which attenuates
invasive property of trophoblasts [63]. This signaling seems
to explain in part shallow invasion that leads to later
preeclamptic condition. Although experimental models and
investigation methods are diﬀerent, it should be carefully
considered the roles of CD105 and sEng in physiological
and pathological conditions of pregnancy in the context of
gestational stages. Trophoblastic expression levels of TGFβ3,
CD105 and its soluble form may be considerably diﬀerent
depending on gestational periods [63, 64]. Fine balance
of angiogenic and antiangiogenic signaling induction at
appropriate time point seems to be very important for
normal placental function.
There are several important factors other than sFlt1 and
sEng that participate in antiangiogenesis in preeclampsia,
and some of them probably function in concert with
VEGFRs-mediated and AT1-mediated signaling pathways.
Serological studies in preeclampsia have elucidated the
involvement of several soluble forms of adhesion molecules
associated with leukocyte traﬃcking. These molecules
include sVCAM-1 (soluble form of VCAM-1, also named
sCD106), sE-selectin (sCD62E), sP-selectin (sCD62P) and
sICAM-1 (also named sCD54). Most of them are reported
to be elevated in preeclampsia, but the results are not always
in agreement [65–67], which may be explained in part by
diﬀerent gestational periods for analysis. In breast cancer
patients who were treated with VEGF inhibitor, plasma level
of sVCAM-1 was reported to be elevated [68]. Since both
preeclampticpatientsandthosewho receiveVEGFinhibitors
are in the condition of disturbed physiological angiogenesis,
these soluble factors are likely to reﬂect endothelial dysfunc-
tion. Maternal-side endothelial cells at basal plate express
E-selectin and P-selectin, and invasive trophoblasts express
cognate ligand of these selectins [69]. If increased sE-selectin
and sP-selectin disturb cellular interaction at basal plate,
they may lead to weakened placental anchorage to uterine
wall. Further investigation is required to understand the
mechanism of these soluble factors that potentially aggravate
fetomaternal condition.Journal of Pregnancy 5
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Figure 2: (a, b): A 40-year-old patient delivered a 736g baby at 27 gestational weeks. Serum creatinine level was 2.06mg/dl at 5 months
after delivery. (a) A glomerulus shows segmental sclerosis and adhesion to Bowman’s capsule (arrowheads). Glomerular capillary wall is
thickenedwithdouble contour(arrows).(PAS, ×400).(b)A collapsingglomerulusrevealingfocal segmentalsclerosis(arrow)withﬁbrinous
exudate (PAS-methenaminesilver, ×400). (c) A 41-year-old patient delivered a 2372g baby at 37 weeks. Proteinuria prolonged for 9 months
after delivery. Upon electron microscopy, subendothelial edema is observed (stars) (×3,000). (d) Diﬀusion abnormalities in a 32-year-old
preeclamptic woman with RPLS. She complained of a headache from the beginning of labor at 37 weeks and lost her consciousness. Blood
pressure was 181mmHg and proteinuria was 8,900mg/day. MRI illustrates the lesion of posterior lobes at the onset of convulsion (left,
arrows). She recovered consciousness in a week, and the lesion diminished completely in 8 months after delivery (right).
6. Role of Renin-Angiotensin System (RAS)
RAS is a mastermind regulator for controlling blood pres-
sure. In addition, RAS participates in a wide variety of
biological activities including vascular remodeling, inﬂam-
mation and tumor development [70–73]. AT1 is a principle
G protein-coupled receptor (GPCR) for angiotensin II,
and AT1 signaling leads to strong vascular contraction by
activating several pathways including ERK and calcineurin
[74, 75], and this activation induces hypertension, edema,
proteinuria and so on [25].
Angiotensin II is not elevated in preeclamptic women,
thus RAS was once thought to be unrelated to the patho-
genesis of human preeclampsia. Later studies, however,
disclosed aberrant activation of AT1-mediated signaling in
preeclamptic patients [76, 77]. In normal pregnancy, mater-
nal circulatory levels of renin and angiotensin II increase,
but hypertension does not occur due to reduced sensitivity
of AT1 to RAS [78]. On the other hand, in preeclampsia,
angiotensin II is not increased but AT1-mediated signaling
pathways are aberrantly activated. There seems to be at
least two mechanisms that accelerate AT1 signaling, that
is, the formation of AT1-bradykinin B2 heterodimers [76],
and agonistic autoimmune antibody against AT1 (AT1-AA)
[77]. As we have discussed, excess sFlt1 is believed to cause
widespread maternal endothelial dysfunction by interfering
with physiological PlGF and VEGF activities. Recent studies
have demonstrated the close association between accelerated
AT1 signaling and sFlt1 production [79, 80]. Stimulation
of AT1 receptor of cultured trophoblasts using IgG from
preeclampticwomenresultedintheelevationofsFlt1in vitro
[81]. Preeclamptic model mice with elevated RAS showed
increased maternal plasma level of sFlt1 in vivo [80].
Calcineurin is a calcium/calmodulin-dependent ser-
ine/threonine protein phosphatase, and it activates the
transcription factor named nuclear factor of activated T cells
(NFAT). NFAT-luciferase activity was signiﬁcantly acceler-
ated in Chinese hamster ovary (CHO) cells stimulated by
IgG of a preeclamptic patient [81]. The overproduction of
sFlt1 was successfully suppressed by calcineurin inhibitor6 Journal of Pregnancy
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Figure 3: Schema of symptoms and signaling relationship between mother and placenta in preeclampsia. Aberrant AT1-mediated signaling
in maternal vasculature and/or shallow invasion of trophoblasts makes the placenta hypoxic. In response, placental villous units produce
sFlt1, sEng, and other proinﬂammatory cytokines that ﬂow into maternal circulation, leading to systemic endothelial dysfunction. The
increase of shear stress in fetoplacental site due to maternal hypertension further aggravates the whole system.
FK506 or calcineurin siRNA in immortalized human tro-
phoblasts cells [81]. These studies indicate that AT1-AA in
maternal circulation potentially triggers calcineurin-NFAT
transcriptional activities through AT1, and that the AT1-
mediated GPCR signaling may disturb VEGFR-mediated
receptor tyrosine kinase (RTK) signaling via calcineurin-
NFAT in preeclampsia. The ﬁndings elucidate the signal-
ing cascade from AT1 activation to VEGF suppression in
preeclampsia. Spatiotemporal association of this cascade
with poor placentation is a subject for future study. A recent
study further demonstrated that AT1-AA was detectable
in fetal cord blood of preeclamptic pregnancy, suggesting
that maternal circulatory AT1-AA might also be available
as a fetal-side marker for evaluating IUGR and other fetal
condition [82].
7.ClinicalManifestations
Imbalance of angiogenic and antiangiogenic molecules and
aberrant signaling cascades derange maternal circulatory
system and then induce characteristic clinical symptoms
including hypertension and proteinuria. We discuss typical
clinical manifestations, and introduce some rodent models
that cause preeclampsia-associated symptoms.
7.1. Hypertension and Proteinuria. Although preeclamptic
patients show heterogeneous symptoms in the context
of disease onset, severity, fetal growth rate and so on,
hypertension and proteinuria are essential phenomena of
this disease. Mechanism of increased vascular resistance and
hypertension is explained in part by insuﬃcient production
of nitric oxide (NO) and prostacyclin (PGI2). NO works as
a potent vasodilator, and angiogenic inhibitors such as sFlt1
and sEng suppress eNOS expression, which in turn reduces
NO production and increases vascular resistance [83, 84].
PGI2, a member of classical eicosanoids, is another eﬀective
vasodilator. It is known that another eicosanoid TXA2 that
induces vasoconstriction is overexpressed in preeclampsia
[85] and that PGI2/TXA2 imbalance contributes to the
development of preeclampsia [86, 87]. The damage of car-
diomyocytes in human preeclampsia is estimated mainly by
functional analysis, and histological information is limited.
Studies of rodent models are informative for the analysis of
these organs that are not available in human patients. In a
study ofRAS-inducedpreeclampticmice, named pregnancy-
associated hypertension (PAH) mice, the cardiac tissues
at term showed severe damages of cardiomyocytes such
as ﬁbrosis and apoptosis in addition to hypertrophy [88].
Although aberrant RAS in this model may not be the case in
human preeclampsia, the increase of sFlt1 in maternal blood
due to accelerated AT1-mediated signaling [80] is common
feature both in this model and human preeclampsia [89].
Proteinuria may be induced not only by the increase
of blood pressure but also by the disturbance of physi-
ological vascular permeability. Under physiological condi-
tion, permeability of capillaries varies among organs and
tissues. For example, cerebral capillaries are particularly
impermeable, named blood brain barrier. On the other
hand, capillary endothelial cells of renal glomeruli are
characterized by fenestrate for ﬁne traﬃc control of ﬂuid
and molecules. Depletion of VEGF from podocytes in a
rodent model led to proteinuria and hypertension [90].Journal of Pregnancy 7
In this model, renal glomeruli were damaged by ﬁbrin
deposit and endotheliosis, suggesting that local eﬀusion of
physiological VEGF from podocytes toward endothelial cells
is indispensable for maintaining fenestrated structure of
glomerular vasculature [90]. Pregnant rats administrated
adenovirus sFlt1 showed glomerular endotheliosis [3]. Such
damages are also detectable in the kidneys of preeclamptic
patients. The renal biopsies of severe preeclamptic patients
showed diﬀuse glomerular endotheliosis, thickenedcapillary
wall and focal sclerotic changes (Figures 2(a) and 2(b)).
Electron microscopy highlighted subendothelial edema in
glomerular capillaries (Figure 2(c)).
7.2. Reversible Posterior Leukoencephalopathy Syndrome
(RPLS). Other life-threatening complications of maternal-
side include HELLP syndrome, pulmonary edema and
eclampsia. Reversible posterior leukoencephalopathy syn-
drome (RPLS, also named posterior reversible encephalopa-
thy syndrome) is the disorder of central nervous system
associated with endothelial dysfunction in blood-brain bar-
rier during and after pregnancies. Clinical and radiological
features of RPLS were initially reported by Hinchey et al.
in 1996 [91]. The most frequent cause of RPLS is believed
to be hypertension, and the term is used not only for
eclamptic condition but also for other endothelial dysfunc-
tion triggered by idiopathic hypertension, drug toxicity,
systemic lupus erythematosus (SLE), and so on. Common
manifestations of RPLS includeheadache, visual disturbance
and seizure [92].The lesion isclearly detectableby head MRI
(Figure 2(d), left). RPLS is essentially curable without post-
complications if treated properly based on anticonvulsion
drugs and blood pressure control after delivery (Figure 2(d),
right). Although many symptoms of eclampsia overlap with
those of RPLS, a few cases of pregnancy-induced RPLS
without preeclampsia have been reported [93, 94]. A reliable
rodent model to analyze preeclampsia-associated RPLS has
not been reported, yet, although PAH mice were reported to
cause convulsion sometimes [95].
8.Summary
Wehavediscussed thepathophysiologyofpreeclampsia from
the points of antiangiogenic signaling pathways. Maternal
susceptibilitytounfavorableproinﬂammatory cytokinesmay
vary among the cases; however, both pathogenetic factors
produced by the placenta and responsive events in maternal
circulationcooperatively developfetomaternal disorders and
may lead to life-threatening conditions (Figure 3). Apart
from the studies on maternal systemic dysfunctions that
have been intensively performed, very limited information
is available about pathological events in fetoplacental-side,
especially during later half of gestation as a fetus is indi-
cated to grow exponentially. Current clinical information is
obtained in most cases from maternal pathological data, and
clinical evaluation of fetal status relies largely on ultrasonog-
raphy and external tococardiography such as contraction
stress test and nonstress test. Further information is neces-
sary about the safety and eﬀects of therapies on whole body
in long-term prognosis. To this end, studies using animal
models are necessary. Although rodent preeclamptic models
may not mimic pathogenesis of human preeclampsia, time-
course analysis of fetal body and the placenta will provide us
with important information about pathological impacts on
fetalwell-being. Abetterunderstanding ofthemolecularand
cellular crosstalks, proinﬂammatory microenvironment and
the eﬀects of antiangiogenic molecules will contribute to the
improvement of eﬀective and safe therapies for preeclampsia
and for those suﬀering from vasculature diseases.
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